Our research explores the intricate molecular mechanisms underlying innate immunity, neuronal death, and human eye diseases. By investigating fundamental biological processes, we strive to uncover insights that may drive groundbreaking treatments. 

07/2025.  Our latest collaborative study, now published in Molecular Psychiatry, identifies the complement C3/C3aR–PF4 axis as a potential therapeutic target for preventing age-related perioperative neurocognitive decline. Congratulations to everyone involved!  [Read the paper] 

05/2025.  Dr. Wang  was selected as an Associate Editor for Journal Eye Open from The Royal College of Ophthalmologists, UK.

03/2025. Dr. Wang recieved a collaboration agreement with Boehringer Ingelheim to develop next-generation therapies for RPE degeneration and geographic atrophy.